VIGL vs. BHVN, ETNB, ANIP, VERA, JANX, EVO, OCUL, MESO, TVTX, and BGM
Should you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Janux Therapeutics (JANX), Evotec (EVO), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry.
Vigil Neuroscience vs. Its Competitors
Vigil Neuroscience (NASDAQ:VIGL) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.
In the previous week, Biohaven had 1 more articles in the media than Vigil Neuroscience. MarketBeat recorded 2 mentions for Biohaven and 1 mentions for Vigil Neuroscience. Biohaven's average media sentiment score of 0.84 beat Vigil Neuroscience's score of 0.00 indicating that Biohaven is being referred to more favorably in the news media.
Vigil Neuroscience has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
83.6% of Vigil Neuroscience shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 18.0% of Vigil Neuroscience shares are owned by company insiders. Comparatively, 16.0% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vigil Neuroscience's return on equity of -111.70% beat Biohaven's return on equity.
Vigil Neuroscience is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Vigil Neuroscience currently has a consensus target price of $10.80, suggesting a potential upside of 35.17%. Biohaven has a consensus target price of $58.46, suggesting a potential upside of 299.60%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Vigil Neuroscience.
Summary
Biohaven beats Vigil Neuroscience on 8 of the 14 factors compared between the two stocks.
Get Vigil Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Vigil Neuroscience Competitors List
Related Companies and Tools
This page (NASDAQ:VIGL) was last updated on 7/4/2025 by MarketBeat.com Staff